Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methcathinone is a synthetic stimulant drug and a structural analogue of methamphetamine and cathinone. It is classified as a synthetic cathinone and is often clandestinely manufactured from readily available chemicals[1][2][3]. Methcathinone acts as a potent central nervous system stimulant with effects similar to amphetamines and cocaine. Its primary mechanism involves inhibition of monoamine reuptake (dopamine, norepinephrine, serotonin) by acting as a substrate for their respective transporters[5][6]. This leads to increased synaptic concentrations of these neurotransmitters. Methcathinone produces euphoria, increased alertness and energy, appetite suppression, enhanced empathy and sociability; adverse effects include hypertension, tachycardia, bruxism (jaw clenching), insomnia or binge use patterns followed by depression or sleep[2][5]. Chronic high-dose use can result in acute mental confusion or psychosis that typically resolves after cessation. The drug has no approved medical uses; it is primarily encountered as an illicit recreational substance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methcathinone.